GordonMD Global Investments LP Portfolio
Auto-discovered active 13F filer.
SEC 13F CIK: 0002039349
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q4 2025 · 13 positions · Total reported value $139.49M · Top-10 concentration 89.7% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 66.7% · 2 new · 6 cut · 4 exited
Active Share (vs S&P 500): 99.7% · vs QQQ: 99.1% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q2 2026 → Q3 2026): -14.1% · vs SPY -16.2% · Prev Value $206.66M — last quarter positions weighted by this quarter price moves · ranking
Est. QTD Return (Q3 2026 → newest close): -10.2% · vs SPY -12.4% · Latest Value $166.47M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking
In its Q4 2025 13F filing, GordonMD Global Investments LP disclosed 13 equity positions with a combined reported value of $139.49M. The filing implies a focused portfolio: its ten largest positions account for 89.7% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.
The largest disclosed positions as of Q4 2025 were KYTX ($41.28M), TEVA ($24.02M), BLCO ($10.48M). By sector, the heaviest allocations are Health Care 92.5%, Other 7.5%.
Versus the prior quarter, GordonMD Global Investments LP opened 2 new positions, trimmed 6 and fully exited 4, a turnover rate of 66.7% of positions.
The largest new positions opened in Q4 2025 were KYTX ($41.28M), TEVA ($24.02M), BLCO ($10.48M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q4 2025)
- KYTX KYVERNA THERAPEUTICS INC · $41.28M
- TEVA TEVA PHARMACEUTICAL INDS LTD · $24.02M
- BLCO BAUSCH PLUS LOMB CORP · $10.48M
- CRNX CRINETICS PHARMACEUTICALS IN · $10.43M
- AMGN AMGEN INC · $7.60M
- RARE ULTRAGENYX PHARMACEUTICAL IN · $7.57M
- TSHA TAYSHA GENE THERAPIES INC · $7.32M
- VIR VIR BIOTECHNOLOGY INC · $5.61M
Fully Exited (vs previous quarter)
No tracked position was fully exited this quarter.
Insider Transactions (Form 4)
Latest GordonMD Global Investments LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
| Transaction date | Activity | Security | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-10-01 | Buy | Pyxis Oncology, Inc. | 5,517,000 | — | SEC filing |
Fund Profile
GordonMD Global Investments LP is an SEC-registered 13F filer based in Beverly Hills, CA, United States. As of Q2 2026 it reported 16 US equity positions with a combined value of $206.66M. HoldingsHub carries 3 quarters of its filings (Q4 2025–Q2 2026).
Firm Snapshot
- Headquarters: BEVERLY HILLS, CA, United States
- SEC registration: 801-128434 (status: Approved), registered 2023-08-01
- Regulatory AUM (Form ADV): $322.27M as of 2026-03-26
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 4 private funds, of which 1 hedge funds
Portfolio Structure
- 16 positions · $206.66M reported value (Q2 2026)
- Top 10 holdings = 83.9% of reported value
- Largest position: KYTX (KYVERNA THERAPEUTICS INC) at 18.3%
- Average position size: $12.92M
Sector Tilt
- Health Care 97.7%
- (classified holdings cover 98% of value)
Quarterly Activity
- Q2 2026: 1 new, 4 added, 2 reduced, 1 exited
- 9 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
4.39M | $41.28M | 29.59% | New | |
| 2 |
|
769.55K | $24.02M | 17.22% | New | |
| 3 |
|
613.47K | $10.48M | 7.51% | New | |
| 4 |
|
224.13K | $10.43M | 7.48% | New | |
| 5 |
|
23.21K | $7.60M | 5.45% | New | |
| 6 |
|
329.10K | $7.57M | 5.43% | New | |
| 7 |
|
1.33M | $7.32M | 5.25% | New | |
| 8 |
|
930.32K | $5.61M | 4.02% | New | |
| 9 |
|
66.68K | $5.46M | 3.91% | New | |
| 10 |
|
54.50K | $5.38M | 3.86% | New | |
| 11 |
|
28.59K | $4.98M | 3.57% | New | |
| 12 |
|
4.12M | $4.74M | 3.40% Form 4 · 1 → |
New | |
| 13 |
|
170.31K | $4.63M | 3.32% | New | |
FAQ
What did GordonMD Global Investments LP buy in 2025-Q4?
In its 2025-Q4 13F filing, GordonMD Global Investments LP reported 13 equity positions worth $139.49M in aggregate; its largest disclosed positions were KYTX ($41.28M), TEVA ($24.02M), BLCO ($10.48M).
How large is GordonMD Global Investments LP's portfolio?
GordonMD Global Investments LP reported $139.49M of long equity holdings across 13 positions as of 2025-Q4. Top-10 holdings account for 89.7% of reported value.
What is GordonMD Global Investments LP's investment style?
HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.